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Abstract
Buruli ulcer (BU) caused byMycobacterium ulcerans is a devastating skin disease, occur-
ring mainly in remote West African communities with poor access to health care. Early case
detection and subsequent antibiotic treatment are essential to counteract the progression of
the characteristic chronic ulcerative lesions. Since the accuracy of clinical BU diagnosis is
limited, laboratory reconfirmation is crucial. However, currently available diagnostic tech-
niques with sufficient sensitivity and specificity require infrastructure and resources only ac-
cessible at a few reference centres in the African endemic countries. Hence, the
development of a simple, rapid, sensitive and specific point-of-care diagnostic tool is one of
the major research priorities for BU. In this study, we have identified a previously unknown
M. ulcerans protein, MUL_3720, as a promising target for antigen capture-based detection
assays. We show that MUL_3720 is highly expressed byM. ulcerans and has no orthologs
in other prevalent pathogenic mycobacteria. We generated a panel of anti-MUL_3720 anti-
bodies and used them to confirm a cell wall location for MUL_3720. These antibodies could
also specifically detectM. ulcerans in infected human tissue samples as well as in lysates of
infected mouse footpads. A bacterial 2-hybrid screen suggested a potential role for
MUL_3720 in cell wall biosynthesis pathways. Finally, we demonstrate that a combination
of MUL_3720 specific antibody reagents in a sandwich-ELISA format has sufficient
sensitivity to make them suitable for the development of antigen capture-based diagnostic
tests for BU.
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Author Summary
According to the recommendations of the World Health Organization, the clinical diagno-
sis of BU should be reconfirmed by at least two laboratory techniques. However, out of the
four currently available tests, three (PCR, histopathology and cultivation ofM. ulcerans)
can only be performed at centralized reference laboratories; the fourth (microscopic detec-
tion of acid fast bacilli) lacks the required sensitivity and specificity. Therefore, a simple
tool for early diagnosis of the disease, which can be implemented in rural health care facili-
ties of the endemic countries, is of urgent need. In this study we aimed at the identification
ofM. ulcerans proteins as potential targets for the development of a simple and rapid diag-
nostic antigen detection assay. Among 36 proteins, MUL_3720 best met the predefined
criteria of being highly expressed byM. ulcerans and not having orthologs in other patho-
genic mycobacterial species prevalent in the endemic regions. Here we generated mono-
clonal and polyclonal antibodies against this protein and carried out pilot studies for the
development of an antigen capture-based diagnostic test.
Introduction
Buruli ulcer (BU) is a neglected mycobacterial skin disease, reported from tropical and sub-
tropical countries world-wide with highest incidence rates in Western Africa [1]. Populations
in rural areas with limited access to health facilities are most affected and often seek medical
advice at late disease stages [2]. Advances in the clinical management of BU have shifted op-
tions for treatment from surgical resection to combination antibiotic therapy [1]. While PCR
analysis targeting the insertion sequence IS2404 has evolved into the gold standard for labora-
tory diagnosis of BU, this test is only available at a few reference centres. Therefore, the diagno-
sis of BU is currently often based on clinical findings and antibiotic therapy is started before
laboratory diagnostic results can be obtained. BU has a wide range of clinical manifestations in-
cluding non-ulcerative forms such as subcutaneous nodules or papules, plaques and oedema,
which may progress to chronic ulcerative lesions. Due to this diversity of disease presentations
the accuracy of clinical diagnosis is limited [1, 3–5] and thus a significant proportion of pa-
tients reporting with skin lesions may not receive adequate treatment. This includes cases of
cutaneous tuberculosis which may be misdiagnosed as BU and thus receive the recommended
eight week course of Streptomycin/Rifampicin combination chemotherapy for BU [5], which is
much too short for the treatment of tuberculosis. As for IS2404 PCR, two of the other three
currently applied methods for laboratory reconfirmation of BU—histopathology and cultiva-
tion of the extremely slow-growing mycobacteria—equally require expensive equipment and
expertise [4, 6–8] not accessible at peripheral health facilities. The only available point-of-care
diagnostic test, direct-smear examination by microscopy for the detection of acid fast bacilli
(AFB), has limited sensitivity and specificity [6]. Hence, one of the major research priorities for
BU is the development of a fast, low-tech, sensitive and specific point-of-care diagnostic test,
which can be directly implemented at peripheral health centres.
The development of a specific point-of-care diagnostic test for the detection ofM. ulcerans
is complicated by the broad antigenic cross-reactivity among the various mycobacterial species.
Serological approaches targeting the fewM. ulcerans-specific antigens identified, turned out to
be not suitable for differentiation between BU patients and exposed control individuals, as
both groups may or may not exhibit serum IgG titers against these antigens [9–11].
In recent years, point-of-care tests in the form of antigen capture assays have successfully
been developed for tropical infectious diseases [12]. Extensive studies focussing on rapid
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diagnostic tests for malaria [13–17] have paved the way for the development of antigen capture
based assays for other diseases such as dengue fever [18, 19], hepatitis C [20, 21] or visceral
leishmaniasis [22] to name but a few.
In the present work we aimed at the identification of targets for the development of an anti-
gen capture test for the diagnosis ofM. ulcerans infection by using a proteomics approach.
Materials and Methods
Ethics statement
Ethical clearance for the analysis of clinical specimens was obtained from the Cameroon Na-
tional Ethics Committee (N°172/CNE/SE/201) and the Ethics Committee of Basel (EKBB, ref-
erence no. 53/11). Immunization of mice for the generation of monoclonal antibodies was
performed in strict accordance with the rules and regulations for the protection of animal
rights (“Tierschutzverordnung”) of the Swiss “Bundesamt für Veterinärwesen”.
All animal infection experiments performed were approved by the animal welfare commit-
tee of the Canton of Vaud (authorization number 2261) and were conducted in compliance
with the Swiss animal protection law under BSL-3 conditions.
Mycobacterial strains
In this study we analyzedM. ulcerans isolates from Ghana (NM20/02), Côte d’Ivoire (ITM
940511), Togo (ITM 970680), China (ITM 98912), Japan (ITM 8756) and Australia (JS5147) as
well as additional mycobacterial strains includingM. abscessus (ATCC 19977),M. avium
(MAC101),M. chelonae (DSM 43804),M. fortuitum (ATCC 49403),M. gordonae (Pasteur
14021.001),M. haemophilum (ATCC 29548),M. intracellulare (clinical isolate),M. kansasii
(NCTC 10268),M. lentiflavum (clinical isolate),M.malmoense (NCTC 11298),M. marinum
(ATCC 927),M. scrofulaceum (Pasteur 14022.0031),M. simiae (clinical isolate)M. smegmatis
(Pasteur 14133.0001),M. terrae (clinical isolate),M. xenopi,M. bovis (ATCC 35734) andM. tu-
berculosis (Pasteur 14001.0001).M. ulcerans strains were grown in BacT/Alert culture bottles
supplemented with enrichment medium according to the manufacturer’s protocol (bioMérieux).
Preparation of protein lysates
For the preparation ofM. ulcerans protein lysates, bacteria (5 ml of culture, OD600~1) were
washed in PBS, heat-inactivated at 95°C for 35 min, centrifuged at 100000 × g for 10 min and
resuspended in 400 μl lysis buffer (PBS containing 5% SDS, 1 mM phenylmethylsulfonyl fluo-
ride (PMSF) and a protease inhibitor cocktail (complete mini, Roche)). The mix was trans-
ferred to lysing tubes (Precellys) and homogenized using a mechanical bead beater device
(Precellys 24, Bertin Technologies) twice at 60800 rpm for 30 s. Beads and non-lysed cells were
removed by centrifugation at 100000 × g for 10 min. The preparation of lysates of other myco-
bacterial species was described previously [9].
2D gel electrophoresis ofM. ulcerans lysates
90 μg of trichloroacetic acid (TCA) precipitatedM. ulcerans (NM20/02) protein lysate was re-
suspended in rehydration buffer (8 M urea, 2% 3-[(3-Cholamidopropyl)-dimethylammonio]-
1-propanesulfonate (CHAPS), 0.5% (v/v) ZOOM Carrier Ampholytes (Invitrogen), 0.002%
bromophenol blue and 0.4% dithioerythritol (DTE)). The mix was incubated with a 3–10 pH
gradient strip (ZOOM Strip; Invitrogen) over night (ON) at room temperature (RT). First-
dimension isoelectric focusing (IEF) was performed on a ZOOM IPG runner (Invitrogen)
using a step voltage protocol (175 V for 15 min, 175–2000 V for 45 min, 2000 V for 2 h). After
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IEF, the strips were incubated for 15 min with equilibration buffer (6 M urea, 50 mM Tris
pH 8.8, 30% glycerol, 2% SDS, 30 mMDTE) followed by a 15 min incubation period with alkyl-
ating solution (6 M urea, 50 mM Tris (pH 8.8), 30% glycerol, 2% SDS, 0.23 M iodacetamide).
Second-dimension gel electrophoresis was performed at 200 V for 35 min using a 10%
NuPAGE Novex Bis-Tris ZOOM Gel (Invitrogen). The gel was stained with Coomassie blue
(Invitrogen).
In-gel tryptic digestion of proteins
All Coomassie stained protein spots were selected for mass spectrometry analysis. Spots were
excised from the 2D gel, placed in a low-binding microcentrifuge tube and destained in 0.1 M
ammonium bicarbonate / 30% acetonitrile at 30°C. Gel spots were dried in a SpeedVac concen-
trator and digested with 4 μl of 10 μg/ml trypsin (trypsin porcine, Roche Applied Science) ON
at 37°C. Peptides were extracted from gel pieces with 4 μl of 0.3% trifluoroacetic adic (TFA) /
50% acetonitrile. The samples were desalted and concentrated using ZipTipC18 tips (Milli-
pore). Eluted peptides were loaded onto a MALDI target.
Mass spectrometry (MS) and data analysis
MS analysis was performed using a MALDI-TOF mass spectrometer (Bruker ultraflex III TOF/
TOF, Bruker Daltonics Inc.) in the reflector mode. 1 μl of tryptic digest and 1 μl of matrix
(5 mg/ml α-cyano-4-hydroxycinnamic acid, 50% acetonitrile, 0.1% TFA) were spotted onto a
MALDI target (MTP AnchorChip 600/384, Bruker Daltonics) and allowed to co-crystallize at
room temperature. Data were processed using FlexAnalysis software (Bruker Daltonics flexAna-
lysis 2.4). Spectra were smoothed (Sawitzgy Golay algorithm, 0.2 m/z width, 1 cycle), baseline
subtracted (median algorithm, 0.8 flatness) and calibrated using trypsin autocleavage or internal
standard peptide mass peaks. A monoisotopic peak list was generated from the spectrum using
SNAP algorithm and analyzed with BioTools (Bruker Daltonics BioTools 3.0). Peptide mass fin-
gerprinting searches were performed using the Aldente search engine on the Expasy server.
Recombinant expression of full length MUL_3720 and truncated
MUL_3720
The full length MUL_3720 (aa 1–207) and a truncated version of this protein lacking the lectin
domain (aa 115–207) were recombinantly expressed in Escherichia coli BL21 Star (DE3, Invi-
trogen) as N-terminal hexahistidin-tagged fusion proteins. Briefly, PCR was performed on a
pUC57 vector containing the DNA sequence of MUL_3720 generated by gene synthesis (Gen-
script), including NdeI and NotI restriction sites. The amplified sequences were inserted into a
TOPO-TA cloning vector using the TOPO Cloning Kit and introduced into E. coli (Top 10,
Invitrogen). The vector was digested with NdeI and NotI (New England Biolabs) and the se-
quence was ligated into a pET28a expression vector using the Rapid DNA Ligation Kit
(Roche). E. coli BL21 Star (DE3, Invitrogen) were grown in Luria-Bertani (LB) medium until
an OD600 of ~0.5. Protein expression was induced by addition of isopropyl thiogalactoside
(IPTG) to a final concentration of 1 mM and subsequent incubation for 3 h at 37°C. Bacteria
were lysed by sonication and His-tagged proteins were purified by nickel-nitrilotriacetic acid
(Ni-NTA) chromatography.
Construction of a MUL_3720 overexpressingM. ulcerans strain
MUL_3720 was amplified from genomicM. ulcerans DNA and cloned into TOPO vector using
NdeI and ScaI restriction sites. Electrocompetent E. coli TOP10 cells (Invitrogen) were
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transformed with TOPO::MUL_3720 vectors and spread onto LB-Ampicillin (50 μg/ml) agar.
Plasmid DNA of the mutant colonies was prepared and inserts with correct size and sequence
were excised from TOPO by NdeI/ScaI and ligated into the mycobacterial vector pSD5. Chemi-
cally competent E. coli TOP10 were transformed with pSD5::MUL_3720 and grown on LB-
Kanamycin (50 μg/ml) plates. Plasmid DNA was prepared and the presence of the insert
was confirmed.
M. ulcerans strain NM20/02 was grown in BacT bottles (bioMérieux) containing enrich-
ment medium (bioMérieux). Bacteria were harvested and washed twice with 10% glycerol or
distilled water. CompetentM. ulcerans bacteria were electroporated (2.5 kV, 1000 Ohm, 25 μF)
with varying amounts (50–1000 ng) of DNA, transferred to MGIT-OADC medium (BD) and
grown under non-selective conditions for 36 hours at 30°C. After the recovery phase, bacteria
were spread on 7H10-Kanamycin (25 μg/ml) agar and incubated for several months at 30°C.
Colonies were picked and regrown on selective agar and in BacT bottles (bioMérieux) in order
to prepare lysates and stocks.
Generation of antibodies against MUL_3720
For the preparation of mAbs, mice were immunized two times intraperitoneally with 40 μg of
recombinant full length MUL_3720 (aa 1–207) emulsified in Immune Easy adjuvant (Qiagen).
Two weeks after the second immunization serum antibody titres against MUL_3720 (aa
1–207) as well as against the truncated MUL_3720 (aa 115–207) were determined by ELISA.
Based on these results one BALB/c mouse was selected to receive a final intraperitoneal injec-
tion of 40 μg of recombinant MUL_3720 (aa 1–207) without adjuvant. Three days after this
last booster dose, hybridoma cell lines were generated as described previously [23]. Briefly, the
spleen of the selected mouse was removed and the spleen cells were fused with mouse myeloma
cells (PAI cells). After a few days, cell culture supernatants were tested for the presence of anti-
MUL_3720 (aa 1–207) as well as anti-MUL_3720 (aa 115–207) antibodies. Positive cell lines
were cloned by limiting dilution and expanded. MAbs were purified using HiTrap rProtein A
column (Amersham Biosciences). Two individual fusion experiments resulted in 24 and 17
MUL_3720-ELISA positive B-cell hybridoma cell lines, respectively. Of these, a total of 5 B-cell
hybridoma cell lines (JD3.1, JD3.2, JD3.3, JD3.4, JD3.6, JD3.7) were successfully cloned and ex-
panded for antibody production.
Rabbit polyclonal antibodies were generated and affinity purified by Eurogentech. New Zea-
land white Rabbits were injected intramuscularly with 20 μg recombinant MUL_3720 (aa
1–27) with Sigma Adjuvant System (SZ3398) or Imject Alum (SZ3403) on day 0, 14, 28 and 56.
Total IgG was purified from antiserum collected on day 66 by protein A
affinity chromatography.
ELISA
96-well Immulon microtiter plates (Thermo Scientific) were coated with 1 μg recombinant
MUL_3720 (aa 1–207) or MUL_3720 (aa 115–207) per well in 100 μl PBS and incubated ON
at 4°C. Plates were washed three times with washing buffer (2.5% Tween 20 in dH2O) and
blocked with 5% non-fat dry milk in PBS containing 0.1% Tween for 1 h at 37°C. After washing
as described above, 100 μl of the primary antibody (mAbs or hybridoma supernatant) was
added and incubated for 2 h at 37°C. Following an additional washing step, 100 μl of 1:300000
diluted goat anti-mouse IgG (γ-chain specific) antibodies coupled to alkaline phosphatase
(SouthernBiotech) was added to each well and incubated for 1 h at 37°C. Plates were washed
and 100 μl/well of phosphatase substrate solution (1 mg/ml p-Nitrophenyl phosphate in
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substrate buffer) was added and incubated for 1 h at 37°C. Absorbance at 405 nm was mea-
sured with a microplate reader (Tecan Sunrise).
Western blot analysis
2 μg of mycobacterial protein lysates per lane were separated on NuPAGE Novex 4–12% Bis-
Tris ZOOMGels (Invitrogen) using NuPAGEMES SDS Running Buffer (Invitrogen) under re-
ducing conditions. After electrophoresis proteins were transferred onto nitrocellulose mem-
branes using an iBlot gel transfer device (Invitrogen). Membranes were blocked with blocking
buffer (5% non-fat dry milk in PBS) ON at 4°C. Membranes were then incubated in blocking
buffer containing anti-MUL_3720 IgG (mouse mAbs JD3.2, JD3.4 or rabbit polyclonal IgG
SZ3398) or mouse mAb DD3.7 (specific for a conserved mycobacterial protein) serving as
loading control for 1 h at RT. After washing, membranes were incubated with secondary goat
anti-mouse IgG (γ-chain specific) (HRP, SouthernBiotech) or goat anti-rabbit IgG (Fc frag-
ment specific) (HRP, Milan) for 45 min at RT. After washing, bands were visualized by chemi-
luminescence using the ECLWestern Blotting substrate (Pierce).
Histology
Immunohistochemical analysis was performed on tissue or punch biopsies from different
IS2404 qPCR reconfirmed patients. Tissue or punch biopsies of BU patients were removed
aseptically and immediately fixed in 10% neutral buffered formalin for 24 hours. Afterwards
the tissue was embedded into paraffin, cut into 5 μm thin sections and transferred onto micros-
copy glass slides. Immunohistochemical staining of the sections was performed after deparaffi-
nisation, rehydration and antigen retrieval with citrate-pretreatment according to standard
protocols [24]. Inactivation of endogenous peroxidase as well as prevention of unspecific bind-
ing was achieved by incubation in PBS containing 0.3% hydrogen peroxide and 1.5% horse
serum for 20 min. Primary anti-MUL_3720 IgG was diluted in PBS containing 0.1% Tween-20
and added to the slides for 1 h at RT or ON at 4°C. After incubation with biotin-conjugated
horse anti-mouse IgG, slides were stained using the Vector ABC and NovaRED system. Sec-
tions were counterstained with haematoxylin.
JD3.4 and JD3.2 showed a comparable staining in intensity, specificity and sensitivity. JD3.2
gave a slightly lower unspecific background staining of the surrounding tissue and was used for
IHC analysis.
Immune fluorescence assay (IFA)
IFA was carried out as described previously [25]. Briefly, a pellet ofM. ulcerans bacteria
(OD600~0.6) was resuspended in 1.5% low-melting agarose (BioWhittaker Lonza, Basel Swit-
zerland) and transferred to cryomodules (Applied BioSystems). Agarose blocks were embed-
ded into paraffin, cut in 3 μm sections and transferred onto microscopy glass slides (Thermo
Scientific). Bacteria were stained with mAb JD3.2 and Alexa fluor488 (Invitrogen) conjugated
goat anti-mouse IgG and mounted in ProLong Gold anti-fade reagent containing 40,6-Diami-
dino-2-phenylindole (DAPI; Invitrogen).
Mycobacterial protein fragment complementation
The system described for investigating protein interactions by the functional reconstitution of
a murine dehydrofolate reductase domain inM. tuberculosis [26] was modified here for use in
M. ulcerans.N-terminal and C-terminal fusions of the bait domains to full length MUL_3720
were constructed using pUAB400 or pUAB200. Cloning was facilitated by theMfeI and ClaI
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restriction sites in the pUAB multiple cloning sites. All cloning was performed using E. coli
DH10B and confirmed by Sanger sequencing. Plasmids were extracted from E. coli using mini-
prep columns (Qiagen) and plasmid DNA was used to transformM. smegmatisMC2155 by
electroporation as previously described [27].
M. ulcerans Agy99 genomic DNA libraries were prepared by partial AciI digestion. Digested
DNA between 500 bp and 3 Kbp was purified using a gel purification kit (Qiagen), ligated into
ClaI digested pUAB300 and used to transform E. coli DH10B. A number of colonies were ran-
domly selected for PCR using primers F102 (50-agaaccaccacgaggagctcat-30) and R102 (50-
tgatgcctggcagtcgatcgta-30) that flank the multiple cloning site on the vector to check for inser-
tions containing inserts within the desired size range [26]. Approximately 2 × 105 clones were
subsequently collected and cultured in LB ON. Plasmid DNAmaxi-preps were performed on
ON cultures according to the manufacturer’s instructions (Sigma-Aldrich).
Bacteria co-transformed with plasmids containing interacting, complementary mDHFR
fragments were selected on 7H11 kanamycin (25 μg/ml) and hygromycin (50 μg/ml) plates.
Colonies were patched onto 7H11 kanamycin-hygromycin-trimethoprim plates and colonies
resistant to trimethoprim were selected for PCR. Using primers F102 and R102, PCR products
were sequenced. The sequences were used to perform BLAST against theM. ulcerans Agy99 ge-
nome. Inserts containing open reading frames in the incorrect orientation were discarded. Also
removed were inserts that matched non-coding genomic DNA or the dehydrofolate reductase
fromM. ulcerans.
Bacteria and mouse foot pad infection model
M. ulcerans strain S1013 used for experimental infection of mice was isolated in 2010 from the
ulcerative lesion of a Cameroonian BU patient [28]. Bacteria were cultivated in Bac/T medium
for 6 weeks, recovered by centrifugation and a stock suspension in sterile PBS of 125 mg/ml
wet weight was prepared. 30 μl of a 1:1000 dilution of the stock solution was injected subcuta-
neously into the left hind foot pad of 14 week old female BALB/c mice. On day 87 after infec-
tion, mice were euthanized and foot pads were aseptically removed. Foot pads were dipped
into 70% ethanol, dried under the laminar flow, cut into four pieces with a scalpel and trans-
ferred to reinforced hard tissue grinding tubes (MK28-R, Precellys) containing 750 μl of Bac/T
medium (bioMérieux). Tissue homogenization was performed with a Precellys 24-dual tissue
homogenizer (3 × 20 s at 5000 rpm with 30 s break). After transferring the supernatant to a
fresh tube, the residual tissue remains were homogenized a second time in 750 μl of Bac/T me-
dium. Tissue lysates were pooled and stored at -80°C until further use. 500 μl of thawed tissue
lysate was transferred into tough microorganism lysis tubes (VK05–2ml, Precellys), inactivated
for 1 h at 85°C and centrifuged at 170000 × g for 5 min. The pellet was resuspended in 250 μl
PBS containing protease inhibitors (Roche, EDTA—free) and cells were disrupted with Pre-
cellys 24-dual tissue homogenizer (2 × 30s at 6800rpm with 1 min break in between). Lysates
were cleared by centrifugation and tested by ELISA.
Antigen capture assay
Nunc-Immuno Maxisorp 96-well plates (Thermo Scientific) were coated with 10 μg/ml JD3.4
mAb (50 μl per well) in PBS and incubated ON at 4°C. Plates were washed three times with
washing buffer (2.5% Tween 20 in dH2O) prior to incubation with blocking buffer (5% non-fat
dry milk in PBS) for 2 h at RT. After washing as described above, 50 μl of different dilutions of
the purified recombinant full length MUL_3720,M. ulcerans lysate (NM20/02), or lysates from
M. ulcerans infected tissue samples in PBS were added and incubated for 2 h at RT. Following
an additional washing step, 50 μl anti-MUL_3720 rabbit IgG (5 μg/ml) in blocking buffer with
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detergent (0.5% non-fat dry milk in PBS containing 0.05% Tween 20) was added and incubated
for 2 h at RT. After washing as described above, 50 μl goat anti-rabbit IgG coupled to horserad-
ish-peroxidase (Milan) diluted 1:100000 in blocking buffer with detergent was added and incu-
bated for 1 h at RT. Plates were washed and TMB peroxidase substrate solution was added.
After 10 min the reaction was stopped with 2 M sulfuric acid and absorbance was measured at
450 nm with a microplate reader (Tecan Sunrise).
Results
Identification of MUL_3720
For identification of suitable proteins that could be used as targets in diagnostic test formats,
anM. ulcerans whole protein lysate was analysed by 2D gel electrophoresis (S1 Fig.). In total,
384 protein spots were detected, processed and subsequently subjected to MALDI-TOF-MS.
Among the 384 spots, 118 peptide fragments were identified and attributed to 36 different
genes. In order to select for proteins without orthologs inM. tuberculosis,M. bovis orM. leprae,
a BLAST search against the Uniprot database was performed for all 36 proteins, resulting in
the identification of three potential targets (MUL_3720, MUL_0343 and MUL_4023) suitable
for a selective antigen capture assay. However, MUL_0343 and MUL_4023 presented very
weak protein spots in the 2D gel, while MUL_3720 showed a high expression level and was
therefore selected for further analysis.
The 624 bpMUL_3720 gene encodes a protein of 207 amino acids, with a molecular mass of
22 kDa. MUL_3720 is predicted to possess an N-terminal bulb-type mannose-specific lectin
domain and a C-terminal peptidoglycan-binding Lysin Motif (LysM) linked by a proline-rich
sequence (Fig. 1). Database comparisons revealed the presence of orthologs with a similar do-
main organisation inM. abscessus (MAB_2373),M. avium,M. colombiense,M. fortuitum,
Fig 1. Schematic presentation of MUL_3720. (A) The MUL_3720 protein consists of a N-terminal B-lectin domain and a C-terminal LysM domain linked by
a proline rich sequence. MUL_3720 was recombinantly expressed in E. coli either as full length (aa 1–207) or truncated protein (aa 115–207) with a N-
terminal hexa-histidine-tag. (B) The predicted amino acid sequence is shown with residues of the B-lectin and the LysM domain marked in red and green,
respectively. The consensus sequence motifs QXDXNXVXY involved in alpha-D-mannose recognition are indicated in bold. Strands (arrows), helixes (bars),
exposed (underlined) and buried (dotted underlined) regions were predicted with PredictProtein.
doi:10.1371/journal.pntd.0003477.g001
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M. kansasii (MKAN_05370),M. marinum (MMAR_3773),M. smegmatis (MSMEG_3662)
andM. xenopi. TheM. marinum ortholog displayed a sequence identity of 99% (S2 Fig.).
Generation and characterization of anti-MUL_3720 antibodies
For the generation of antibodies against MUL_3720, required for the detection of the protein
in diagnostic assays, we immunized mice and rabbits with the full length protein, recombi-
nantly expressed as a His-tagged fusion protein (predicted molecular mass 24 kDa) in E. coli
BL21. Hybridoma cell lines producing antibodies against different epitopes of the protein were
identified by analyzing their reactivity against MUL_3720 (aa 1–207) as well as the truncated
version of MUL_3720 (aa 115–207), lacking the lectin domain and consisting only of the LysM
motif and the proline-rich sequence. Five mAbs (JD3.2, JD3.3, JD3.4, JD3.6 and JD3.7), all of
them mouse IgG1(κ) isotype, were generated, purified and further characterized. All the mAbs
recognized recombinant full length MUL_3720 (aa 1–207) in ELISA. While all antibodies ex-
cept for JD3.6 recognized recombinant full length MUL_3720 (aa 1–207) in Western Blot anal-
ysis (Fig. 2A), only JD3.2 and JD3.4 also reacted with recombinant truncated MUL_3720 (aa
115–207) (Fig. 2B) and the endogenous protein inM. ulcerans lysates (Fig. 2C) (S1 Table).
Reactivity of the generated antibodies with lysates of different
M. ulcerans strains and other mycobacteria
The ability of mouse mAbs JD3.2 and JD3.4 to detect endogenous MUL_3720 in lysates of
M. ulcerans strains from different geographical regions was examined byWestern Blot analysis.
While the protein was recognized by JD3.2 and JD3.4 in allM. ulcerans strains, isolates belong-
ing to the classicalM. ulcerans lineage (Ghana, Côte d’Ivoire, Togo and Australia) showed
higher expression levels as compared to isolates belonging to the ancestral lineage (China and
Japan) (Fig. 3).
Interspecies cross-reactivity of MUL_3720 was determined by Western Blot analysis with
lysates of a range of different mycobacterial species (Fig. 4). In accordance with the BLAST
Fig 2. Reactivity of MUL_3720-specific antibodies.Mouse mAbs JD3.2 (1), JD3.3 (2), JD3.4 (3), JD3.6 (4) and JD3.7 (5) and rabbit polyclonal IgG
SZ3398 (6) and SZ3403 (7) were tested for their reactivity with MUL_3720 (aa 1–207) (A), truncated MUL_3720 (aa 115–207) (B) and the endogenous
MUL_3720 in a total protein lysate ofM. ulcerans strain NM20/02 (C) by Western Blot analysis.
doi:10.1371/journal.pntd.0003477.g002
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search for MUL_3720 orthologs (S2 Fig.), rabbit polyclonal anti-MUL_3720 IgG reacted with
proteins in lysates ofM. fortuitum,M. marinum,M. smegmatis andM. xenopi. In agreement
with a shorter linker between the lectin and the LysM domains (S2 Fig.), theM. xenopi ortholog
was detected at a lower molecular weight. The predicted orthologous proteins inM. abscessus,
M. avium andM. kansasii were not recognized by the rabbit polyclonal IgG. Furthermore, a
protein band was observed in lysates ofM. gordonae,M. malmoense andM. terrae for which
no sequence information is available (Fig. 4A). The detected proteins inM. malmoense and
M. terrae were slightly smaller than MUL_3720.
Analysis with JD3.4 led to a similar staining pattern among the mycobacterial lysates, except
for the protein expressed byM. gordonae, which was not recognized (Fig. 4B). JD3.2 only re-
acted with protein in lysates ofM. malmoense andM. marinum, suggesting that the two mAbs
JD3.2 and JD3.4 recognize different epitopes of MUL_3720 (Fig. 4C).
Localization of MUL_3720
In order to confirm the expression of MUL_3720 byM. ulcerans and the ability of the anti-
MUL_3720 mAb JD3.2 to detect the protein in vivo, we performed immunohistochemistry and
immunofluorescence stainings.M. ulcerans could be detected in punch biopsies of human BU
patients with the mAbs JD3.2 (Fig. 5) and JD3.4. ZN staining (Fig. 5 A, C, E) and JD3.2 staining
(Fig. 5 B, D, F) of serial sections showed identical localization at the same tissue region. AFBs
detected by ZN staining in tissue sections revealed a homogeneous staining pattern, whereas
immuno-staining with mAb JD3.2 exhibited a heterogeneous staining pattern of the bacteria
with intensively stained poles (Fig. 5), indicating a higher expression of the protein in these
areas in the natural environment of the bacteria. In contrast, IFA of in vitro cultivated bacteria
showed a more homogeneous distribution of the protein on the bacterial cell surface. This lo-
calization was confirmed in a MUL_3720 overexpressingM. ulcerans strain (Fig. 6).
Investigation of MUL_3720 function
As a first step to begin to understand the role of MUL_3720 we used a bait and prey approach
to identify otherM. ulcerans proteins that interacted with this protein. We employed the
Fig 3. MUL_3720 is expressed byM. ulcerans strains of various geographic origin. Total protein lysates
ofM. ulcerans strains from Ghana, Côte d’Ivoire, Togo, China, Japan and Australia were analyzed by
Western Blot. Detection with mAbs JD3.2 (A) and JD3.4 (B) demonstrates expression of MUL_3720 in
strains from different geographical regions, while staining with mAb DD3.7 served as a loading control.
MUL_3720 expression levels are lower inM. ulcerans strains belonging to the ancestral (China, Japan) as
compared to those of the classical lineage (Africa and Australia).
doi:10.1371/journal.pntd.0003477.g003
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mycobacterium-specific protein fragment complementation (M-PFC) system. An M-PFC bait
clone using a N-terminal fusion of MUL_3720 and co-transformation with a random library of
M. ulcerans genomic DNA fragments in pUAB300 (prey) resulted in approximately 150 tri-
methoprim resistant colonies. Subsequent clones were patched and screened using primers
F102 and R102 to determine the identity of the DNA sequence present in pUAB300 (Table 1).
Multiple independent clones were identified for sequences encoding DesA1 (MUL_0445) and
a PE-PGRS protein (MUL_0572), together with 13 other single-hit CDS, including an interac-
tion with MUL_3720 itself. Many of the putative interacting proteins had a predicted cell wall
location or role in cell wall biosynthesis, in line with the localization data for MUL_3720
Fig 4. Analysis of mycobacterial lysates for the presence of MUL_3720 orthologs. Total protein lysates
of different mycobacterial strains were analyzed byWestern Blot. MAb DD3.7 served as a loading control. (A)
Detection with pAb SZ3398 demonstrates expression of MUL_3720 orthologs in some of the mycobacteria
tested, but not inM. tuberculosis andM. bovis. (B) MUL_3720 orthologs in additional mycobacterial species
were detected with JD3.4, indicating the recognition of different protein epitopes. (C) Analysis with mAb
JD3.2 led to the detection of MUL_3720 orthologs inM. malmoense andM. marinum.
doi:10.1371/journal.pntd.0003477.g004
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revealed by mAb staining (Table 1 and Fig. 6). No interacting proteins were identified using
the C-terminal MUL_3720 bait fusion, consistent with the predicted cell wall location for this
domain of MUL_3720. The M-PFC detects cytoplasmic protein-protein interactions only [26].
Development of an antigen capture assay using the generated
immunological reagents
We analyzed different combinations of the generated mAbs and polyclonal IgG as MUL_3720
capturing and detecting antibodies in an antigen capture sandwich ELISA. The application of
mAb JD3.4 as capturing and polyclonal rabbit IgG as detecting reagent enabled a highly sensi-
tive detection of recombinant MUL_3720 (Fig. 7A) and the endogenous protein present in ly-
sates of in vitro cultivatedM. ulcerans (Fig. 7B).
In order to test if the antigen capture ELISA is able to detect MUL_3720 expressed by bacte-
ria in infected tissue samples, we analyzed lysates ofM. ulcerans infected mouse foot pads.
MUL_3720 could be detected in lysates of all five infected tissue samples analyzed, while only
background readouts were obtained for lysates of uninfected foot pads (Fig. 8).
Fig 5. Immunohistochemical analysis ofM. ulcerans using anti-MUL_3720 antibodies. Histological sections were either stained with carbolfuchsin
(counterstain methylenblue) (A, C, E) or with specific monoclonal antibodies (JD3.2) against MUL_3720 (B, D, F). (A) A punch biopsy of a BU patient showing
the typical histopathological hallmarks of an active lesion and harbouring large clusters of AFBs inside the subcutaneous tissue (purple clumps) is depicted.
(B) Staining of the same tissue specimen with anti-MUL_3720 antibodies. Serial sections were stained by ZN (C) and anti-MUL_3720 antibodies (D). While
the whole bacterium is stained by ZN (E) single dots are detected by using anti-MUL_3720 antibodies (F).
doi:10.1371/journal.pntd.0003477.g005
Development of Point-of-Care Diagnostics for BU
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003477 February 10, 2015 12 / 18
Discussion
Attempts to develop a diagnostic tool based on serological approaches have been equivocal
[9–11], so we decided to focus on direct detection ofM. ulcerans antigens in BU patient speci-
mens. In the present study, we identified the MUL_3720 protein as a promising target in anti-
gen capture-based diagnostic tests forM. ulcerans. Based on 2D gel electrophoretic analyses,
MUL_3720 is one of the most highly expressed proteins in vitro. The high expression of
MUL_3720 is considered an advantage with respect to developing a sensitive antigen detection
test for the diagnosis of BU.
While the biological role of MUL_3720 is not known, clues to its function are suggested by
its two-domain structure—a conserved bulb-type mannose-binding lectin domain and a Lysin
Motif (LysM) domain—predicted to be involved in alpha-D-mannose recognition and in bind-
ing to peptidoglycan, respectively. Some bacterial species retain certain proteins attached to
peptidoglycan by their LysM domains [29]. We used a mycobacteria-specific two-hybrid sys-
tem to search forM. ulcerans proteins interacting with MUL_3720 and we had hits to a range
of proteins known or predicted to be cell-wall associated or involved in cell wall synthesis
(Table 1). Many of the interacting proteins—such as DesA1 (Table 1)—are involved in biosyn-
thesis or modification of cell wall molecules. In other mycobacteria, the resulting double bonds
from the DesA1-mediated catalysis of a desaturation reaction of saturated alkyl chains that
arise during mycolic acid synthesis are required for subsequent position specific modifications
such as epoxidation and cyclopropanation of this key cell wall metabolite [30, 31].MUL_3720
appears to be arranged in an operon structure with two adjacent putative cell wall-associated
Fig 6. Localization of MUL_3720. Localization of MUL_3720 in the wildtype or overexpressing M. ulcerans
strain. (A) IF analysis (magnification 1000x) shows that MUL_3720 is homogeneously distributed at the cell
surface. Primary JD3.2 anti-MUL_3720 antibody was used at a concentration of 0.1 μg/ml. Bars: 2 μm (B)
Western Blot analysis ofM. ulcerans lysates underlines the high expression of MUL_3720 by the mutant
strain. As for the IFA analysis, JD3.2 anti-MUL_3720 antibody was used at a concentration of 0.1 μg/ml. A
GroEL-antibody was included as loading control.
doi:10.1371/journal.pntd.0003477.g006
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protein coding genes (MUL_3721,MUL_3722). Immunofluorescence stainings ofM. ulcerans
bacilli confirmed the cell wall localization of MUL_3720.
With its cell wall location, the two-domain structure including a mannose-binding N-
terminal cytoplasmic component and C-terminal peptidoglycan-binding component, its
Table 1. List of proteins interacting with the N-terminus of MUL_3720 as determined by M-PFC assay.








MUL_0445 Desaturase, DesA1 339 1–84 CYT 3
MUL_0572 PE-PGRS family protein 890 360–478 INT 2
MUL_2853 PE-PGRS family protein 403 1–236 INT 1
MUL_3720 Conserved protein 208 179–207 CYT 1
MUL_4703 Conserved hypothetical protein 571 1–251 CYT 1
MUL_4714 Conserved integral membrane protein 464 380–463 INT 1
MUL_1239 Transmembrane ATP-binding protein ABC
transporter
691 570–690 INT 1
MUL_2018 Phenolpthiocerol synthesis type-I polyketide
synthase, PpsB
1515 1411–1514 INT3 1
MUL_2998 Hydrogen peroxide-inducible genes
activator, OxyR
315 1–180 CYT 1
MUL_0568 Alpha-D-glucose-1-phosphate thymidylyl-
transferase, RmlA
289 9–288 CYT 1
MUL_1214 Conserved transmembrane protein 317 139–316 INT3 1
MUL_4825 Conserved protein 69 1–68 CYT3 1
MUL_4327 Cutinase, Cut5 232 159–231 SEC 1
MUL_0656 Mannosyltransferase, PimB 384 264–383 CYT 1
MUL_4092 3-ketoacyl-(acyl-carrier-protein) reductase 247 158–246 CYT 1
Notes: 1Location is based on BLASTp searches of pUAB300 clones identified as interacting partners and relative to the M. ulcerans Agy99 sequence
2Number identified indicates the number of independent clones generated with this assay. The predicted location is based on at least one cellular location
prediction search using psortB, lipoP, signalP and secretomep. 3Detected in the membrane fraction by proteomics (Tafelmeyer ref). CYT: cytoplasm, INT:
integral membrane protein, SEC: secreted.
doi:10.1371/journal.pntd.0003477.t001
Fig 7. Sandwich ELISA capturing MUL_3720. Antigen capture sandwich ELISAs using mAb JD3.4 in combination with polyclonal anti-MUL_3720 rabbit
IgG as capturing and detecting antibodies, respectively, were carried out to detect serial dilutions of recombinant MUL_3720 (A) and the endogenous
MUL_3720 present inM. ulcerans lysates (B).
doi:10.1371/journal.pntd.0003477.g007
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operon structure and a substantial list of potential interacting proteins, MUL_3720 may be an
adaptor protein for multiple cell wall biosynthetic pathways. MUL_3720 might play a role in
cell attachment and cell-cell interactions given its presence at the cell surface as revealed by
immunofluorescence microscopy and immunohistochemical analyses.
The cell-surface localization of MUL_3720 is an additional advantage with respect to devel-
oping a sensitive diagnostic test, since the protein is expected to be easily accessible and detect-
able in tissue specimens of BU lesions. Potential shedding of the protein from the cell surface
may facilitate ready detection in body fluids, which will be examined in future experiments.
Monoclonal and polyclonal antibodies against MUL_3720 were generated for the develop-
ment of antigen capture assays. These antibodies recognized in vitro grownM. ulcerans bacilli
as well as bacteria in biopsies of human BU patients, proving the expression of MUL_3720 in
BU lesions.
Since these antibodies did not react with orthologs of MUL_3720 in other pathogenic myco-
bacterial species prevalent in the BU endemic regions, prospects for the development of a test
with the desired specificity, excluding in particular cutaneous tuberculosis [5], are good. The
monoclonal antibodies used for the antigen capture test bind to an epitope on the proline/rich
linker and/or the LysM domain. Since the LysM domain is a widespread protein module pres-
ent in more than 4000 proteins of both prokaryotes and eukaryotes [29], the potential cross-re-
activity of the anti-MUL_3720 antibodies with those proteins remains to be analyzed.
Fig 8. Detection of MUL_3720 inM. ulcerans infectedmouse foot pads. Antigen capture sandwich
ELISAs using mAb JD3.4 in combination with polyclonal anti-MUL_3720 rabbit IgG as capturing and detecting
antibodies, respectively, were carried out to detect MUL_3720 in lysates of mouse foot pads infected with
M. ulcerans. Lysates of non-infected mouse foot pads served as negative control. Purified recombinant
MUL_3720 was included as positive control. Asterisks indicate significant differences (P< 0.0001) between
mean ODs of infected and non-infected mouse foot pad lysates using a two-tailed Student’s t test.
doi:10.1371/journal.pntd.0003477.g008
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Importantly, this capture assay specifically detected MUL_3720 protein in tissue lysates of
M. ulcerans infected mouse footpads. Furthermore, initial results revealed that MUL_3720
could be detected in swab samples from human BU lesions with a high bacterial burden (man-
uscript in preparation). Ongoing optimization of the applied reagents as well as the assay for-
mat is aiming at the development of a simple test format appropriate for low-resource
laboratory settings with suitable test sensitivity.
Antibiotic treatment of BU in its early stages leads in most of the cases to complete healing
of the lesions with little or no trauma, whereas treatment at later stages often requires adjunct
surgical treatment and is associated with prolonged hospitalization and long-term sequelae.
The development of a simple and rapid diagnostic test, whose key elements are provided in the
work presented here, will be of immediate benefit to BU patients in rural endemic communi-
ties. Clinical findings could directly be reconfirmed by this point-of-care test helping to avoid a
false diagnosis and to facilitate a prompt onset of adequate treatment.
Supporting Information
S1 Fig. Two-dimensional gel electrophoretic analysis ofM. ulcerans proteins. 2D gel of
M. ulcerans total protein lysate run on a pH3-10 first dimension IPG strip and subsequently
run on a 10% SDS-PAGE gel. Coomassie stained protein spots were excised, in-gel digested
with trypsin, and subjected to MALDI-TOFMS. Identified proteins are marked as green dots
and labelled with the corresponding accession number. Red dots represent proteins that could
not be identified. The spots representing MUL_3720 are indicated with an arrow.
(TIF)
S2 Fig. Sequence alignment of MUL_3720 and orthologs in other mycobacterial species.
Multiple sequence alignment ofM. ulceransMUL_3720 and its orthologs inM. kansasii,
M. abscessus,M. colombiense,M. fortuitum,M. smegmatis,M. marinum,M. avium and
M. xenopi.
(TIF)
S1 Table. Specificity of anti-MUL_3720 mouse mAbs and rabbit polyclonal IgG. All anti-
bodies recognized recombinant full length MUL_3720 (aa 1–207), while JD3.2 and JD3.4 as
well as the polyclonal IgG also reacted with recombinant truncated MUL_3720 (aa 115–207)
and the endogenous protein inM. ulcerans lysates.
(TIF)
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